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Background.
Reported allergy to beta-lactam antibiotics is common and often leads to unnecessary avoidance in patients who could tolerate beta-lactam therapy. In fact, the majority of reported prior reactions are misclassified as allergies; moreover, many individuals with true prior IgEmediated reactions have loss of hypersensitivity over time [1, 2] .
Carrying a label of beta-lactam allergy is not inconsequential. Patients with reported allergies may be treated with alternative agents that can be clinically inferior [3] , and pose increased risks of harm [4, 5] . Furthermore, alternative agents frequently have a broader spectrum of activity and may contribute to the emergence and spread of drug-resistant organisms [5] .
Correctly confirming or refuting allergies to enable receipt of beta-lactam therapy, when indicated, is an important function of antibiotic stewardship [6] [7] [8] [9] [10] . Beta-lactam antibiotic agents are recommended first-line therapies for many infectious syndromes [6] [7] [8] [9] . Currently, Infectious Diseases consultants make great efforts to verify details of reported prior allergies to beta-lactam agents in order to determine whether or not they can be safely prescribed. When history suggests a significant, IgE-mediated allergy, patients often receive non-preferred therapy because it is judged to be the safest option for the patient.
Whether or not the risk of allergy from beta-lactam use in some patients reporting allergy is outweighed by the toxicity or potentially inferior efficacy associated with alternate therapies has not been systematically evaluated. We hypothesized that receipt of alternative therapy when a beta-lactam agent is the preferred therapy, would lead to worse clinical outcomes. To test this hypothesis, we conducted a trainee-led prospective cohort study to determine the burden and clinical impact of reported beta-lactam allergy on patients seen by the Infectious Diseases consultation service at three academic hospitals.
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Methods.
This study was developed and initiated by Infectious Diseases residents as the initial phase of a division-wide, trainee-led quality improvement initiative [11] , and took place at three academic hospitals: (1) Toronto General Hospital (417 Beds), (2) Mount Sinai Hospital (442 Beds), and (3) Sunnybrook Health Sciences Centre (824 Beds). Toronto General Hospital and Mount Sinai Hospital share the same teaching service and were considered jointly (TGH/MSH), whereas Sunnybrook Health Sciences represented a separate teaching service (SHSC). A pointof-care electronic data entry system was used by participating trainees for prospective data collection. Research Ethics Board approval was received at all participating hospitals. The need for individual patient consent was waived.
Eligibility
The study population was comprised of all inpatients seen in consultation by the Infectious Diseases services at the participating hospitals between April 2014 and January 2015 on days that the subspecialty Infectious Diseases resident was present for the review of cases. The days Infectious Diseases residents were present included both weekdays and weekends; they were routinely absent for one half-day per week of scheduled teaching, without other systematically excluded days. Only initial patient assessments were considered; repeat consultations were not included in the analysis.
Prospective Assessment of Beta-Lactam Allergy
Participating Infectious Diseases residents recorded study data, using encrypted database software on password-protected tablets, during consultation review rounds on the days they were present on service. The following variables were collected at the time of patient consultation:
Historical (history of beta-lactam allergy, characterization of previous allergic reaction [ (1) 
Review of Patient Outcomes
Additional patient variables and outcome data were collected and abstracted in a second data collection step by two trainees, occurring after the initial assessment by the clinical service using comprehensive electronic medical records (including scanned medical documents). 
microbiologically confirmed Clostridium difficile infection (CDI) within 3 months of antibiotic initiation, acute kidney injury defined by RIFLE Injury Criteria as >50% reduction in glomerular
A c c e p t e d M a n u s c r i p t 5 filtration rate or doubling of baseline creatinine [13] , and other adverse reactions attributed to antibiotic use). The index admission was considered as the time frame up until discharge or inhospital death. We did not capture specific data on readmission diagnoses apart from whether or not they were associated with the index infection. Point-of-care data was also confirmed during the clinical review process where possible. In order to confirm reproducibility of data abstraction, 7 key covariates among 10% of cases were randomly chosen and double-abstracted by independent chart reviewers, and a kappa statistic of inter-user variability was calculated, which was determined to be 94%. Two Infectious Diseases physicians reviewed the final data for completeness, clinical accuracy, and to resolve any discrepancies.
Data Analysis
The primary pre-determined outcome was treatment-related adverse event. This was comprised of any of the following outcomes: (1) acute kidney injury while on treatment, (2) CDI (within 3 months of treatment), (3) suspected drug-related adverse reaction while on treatment and requiring discontinuation, or (4) readmission with the same infection. The individual outcomes, along with mortality, were also evaluated as secondary endpoints. In order to evaluate the impact of reported beta-lactam allergy on these outcomes, we categorized the main predictor variable as follows: (i) patients with no reported beta-lactam allergy; (ii) patients with reported beta-lactam allergy and preferred therapy was not a beta-lactam agent; (iii) patients with reported beta-lactam allergy for whom preferred therapy was a beta-lactam agent and the preferred betalactam agent was administered; (iv) patients with a history of reported beta-lactam allergy for whom the preferred treatment was a beta-lactam agent, but an alternative antibiotic agent was administered. While uncommon, if an individual with a reported beta-lactam allergy received a beta-lactam agent, but it was not the preferred beta-lactam agent, they were classified as category (iii). Univariate analysis of the primary and secondary outcomes was performed using Chi-square or Fisher's exact testing. Multivariable logistic regression analysis, with the primary outcome of 
Results.
Of 542 patients receiving antibiotic therapy, 21 (4%) were excluded due to incorrect linkage data, 5 (1%) were excluded due to incomplete data, and 9 (2%) were excluded due to duplication. Baseline characteristics of the 507 patients receiving antibiotic therapy, stratified by report of beta-lactam allergy and preferred/chosen therapy, are shown in Table 1 . Additional characteristics are available in Table 2 . Of 95 (19%) patients with reported beta-lactam allergy, preferred therapy was a beta-lactam agent in 72 (76%) cases and non-beta-lactam agents in 23 (24%) cases. In the group of patients with reported beta-lactam allergy, when beta-lactam was considered preferred therapy, 47 (65%) received a beta-lactam agent, while 25 (35%) received non-beta-lactam therapy. Less than half (48%) of patients who reported beta-lactam allergy and did not receive preferred beta-lactam therapy reported a history of a severe reaction, which was significantly higher than in the group reporting beta-lactam allergy that received preferred betalactam therapy (15%), p=0.004.
Univariate and multivariable analyses are presented in Table 3 and Table S1 . Patients with reported beta-lactam allergy that did not receive preferred beta-lactam therapy were more likely to have an adverse event compared to those who did not report beta-lactam allergy (unadjusted odds ratio 3.43, 95%CI 1.48-7.96). This primary endpoint was driven largely by increased rates of readmission and adverse reactions (requiring discontinuation of therapy), which A c c e p t e d M a n u s c r i p t 7 were both significantly more frequent than in the group of patients not reporting beta lactam allergy. There were no significant differences in mortality when compared to patients not reporting allergy.
After adjusting for potential confounders, multivariable logistic regression analysis confirmed that patients reporting beta-lactam allergy who did not receive preferred beta-lactam therapy were more likely to have an adverse outcome than those patients not reporting betalactam allergy (adjusted odds ratio 3.18, 95%CI 1.28-7.89). There was no significant difference in adverse outcomes detected between patients with reported beta-lactam allergy who nonetheless received preferred beta-lactam therapy, compared with those who did not report beta-lactam allergy (adjusted odds ratio 1.33, 95% CI 0.62-2.87). In order to adjust for possible confounding by a diagnosis of bacteremia without an identified primary source, an unbalanced diagnosis across the groups (Table 2) , we performed an additional regression analysis by adding this diagnosis into the existing logistic regression model, which yielded no significant change in the results (Table S1 ). Moreover, when restricting the study population to either (i) only those surviving to discharge, or (ii) only those surviving to discharge or event, both analyses resulted in no significant changes to the findings (Table S1 ).
Discussion
In this multicenter prospective cohort study of inpatients seen by Infectious Diseases consultation services, reported beta-lactam allergy was common and led to a significant proportion of patients receiving alternative antimicrobial therapy. This avoidance of preferred beta-lactam therapy was associated with increased adverse outcomes, including readmission to hospital and adverse reactions requiring discontinuation of therapy.
The impact of carrying a label of beta-lactam allergy has been documented in prior retrospective studies. One single-center study suggested increased mortality rates and intensive care admissions among patients labelled as having a penicillin allergy [4] . Another retrospective A c c e p t e d M a n u s c r i p t 8 cohort study of 51,582 patients found that carrying a label of penicillin allergy was associated with prolonged length of stay, an increased rate of CDI, as well as acquisition of antibioticresistant organisms, such as vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA) [5] .
In contrast, the prospective nature of our study allowed us to determine the patient's preferred therapy and best available allergy history, and to determine the impact of reported allergy on clinical care decisions and outcomes. This analysis suggests that increased adverse events among patients labelled with a beta-lactam allergy may be a consequence of use of alternative antibiotic therapy. In fact, those who received preferred beta-lactam therapy despite reporting allergy had a similar risk of adverse outcomes compared to patients not reporting allergy. Interestingly, one prior study found no increase in the rates of readmission among those reporting beta-lactam allergy [4] , possibly due to the inability to separate out the patients who received preferred beta-lactam therapy despite their allergy label. Of note, a previous study in a tertiary care center in Quebec, Canada noted that 61% of patients with a history of beta-lactam allergy received beta-lactam therapy, similar to our findings, however it was not specified in the study whether they received the specific preferred beta-lactam [14] .
The increased readmissions noted among the patients reporting beta-lactam allergy who did not receive preferred beta-lactam therapy has at least two plausible explanations. First, alternate therapies often represent inferior treatment to beta-lactams. For example, vancomycin treatment for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia, is associated with recrudescence of disease [3] . Second, adverse reactions to certain non-beta-lactam drugs occur with higher frequency than reactions to beta-lactam agents, which may also contribute to readmission during the course of treatment [15] .
It is worth highlighting that the risk of antibiotic-related reactions that required discontinuation of therapy was higher among all patients carrying a label of beta-lactam allergy, regardless of whether or not they received preferred beta-lactam therapy. This finding may be at University of New Mexico on July 27, 2016 http://cid.oxfordjournals.org/ Downloaded from A c c e p t e d M a n u s c r i p t 9 related to the underlying propensity for multiple drug allergies in some patients [16] . It is possible that the preponderance of women that did not receive preferred therapy could have been due to a higher prevalence of Multiple Drug Allergy Syndrome in females [13] , however sex based adjustment was performed in the analysis. Although there were differences in the classes of antibiotics received by patients reporting beta-lactam allergy, including agents known to increase the development of CDI (fluoroquinolones and clindamycin) [17] , there was no difference in the incidence of CDI, which may be related to sample size and to the significant use of antibiotic therapy associated with CDI (third-generation cephalosporins) in patients not reporting betalactam allergy.
Recently, the Association of Medical Microbiology and Infectious Diseases (AMMI)
Canada released its Choosing Wisely statements which included the declarative statement: "Don't prescribe alternate second-line antibiotics to patients reporting non-severe reactions to penicillin when beta-lactams are the recommended first-line therapy" [18] . In our study, the avoidance of beta-lactam therapy in patients for whom beta-lactam therapy was preferred, occurred more frequently among patients with more 'serious' allergy histories, in keeping with an increased degree of physician caution. Despite this, over one-third of patients who had a clinical indication for beta-lactam therapy did not receive preferred treatment due to reports of simple rashes, suggesting marked room for improvement in the prescribing of preferred beta-lactam therapy in these patients. In this context, the Centre for Disease Control recently published an educational fact sheet to raise awareness regarding the unnecessary broad-spectrum antibiotics prescribed for patients with penicillin allergy [19] . This study has several limitations. One limitation is the use of a composite outcome, which was required to generate sufficient power over the anticipated study period, but which limited the ability to analyze all of the outcomes individually. However, the composite outcome is comprised of clinically relevant individual outcomes and reflects treatment-related adverse outcomes as a whole. A second limitation is that the impact of reported beta-lactam allergy among patients encountered on the Infectious Diseases consultation services may be more significant compared to other hospitalized patients. However, the prevalence of beta-lactam allergy as a whole in our sample is not largely different than population estimates [24, 25] , and suggests this sample was not heavily biased to referral by allergy history alone. Moreover, Infectious Diseases consultants are often consulted for complex cases, illustrated by the A c c e p t e d M a n u s c r i p t 11 prolonged length of stay (10-15 days) compared to average ranges for the hospitals (5-7 days), underscoring the importance of optimizing antibiotic treatment in these patients. Lastly, due to the nature of the outcome data abstraction, it was not possible to blind abstractors to the exposure at the time of consultation and initial data entry, however during the double abstraction evaluation, the abstractors were blinded, and a high kappa was still achieved, arguing against the presence of differential misclassification.
Our multicenter prospective cohort study suggests that avoidance of preferred betalactam therapy in patients who report allergy is associated with an increased risk of adverse events. Since more than half of patients receiving alternate therapy had non-severe allergy histories, increasing beta-lactam use in these patients may improve patient outcomes.
Development of inpatient programs aimed at accurately identifying beta-lactam allergies, to safely promote beta-lactam administration among these patients, is warranted.
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